These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 32997282)
1. REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal. Batista S; Nunes CC; Cerqueira JJ; Martins Silva A; Correia de Sá J; Ferreira J; Mendonça MT; Pinheiro J; Salgado V; Correia AS; Sequeira J; Costa A; Sousa L Neurol Sci; 2021 May; 42(5):1995-2003. PubMed ID: 32997282 [TBL] [Abstract][Full Text] [Related]
2. The effectiveness of fingolimod in a Portuguese real-world population. Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621 [TBL] [Abstract][Full Text] [Related]
3. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA). Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799 [TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months. Tichá V; Počíková Z; Vytlačil J; Štěpánová R BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205 [TBL] [Abstract][Full Text] [Related]
5. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. Izquierdo G; Damas F; Páramo MD; Ruiz-Peña JL; Navarro G PLoS One; 2017; 12(4):e0176174. PubMed ID: 28453541 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice]. Alcala-Vicente C; Perez-Miralles FC; Gascon-Gimenez F; Bosca-Blasco I; Navarre-Gimeno A; Coret-Ferrer F; Casanova-Estruch B Rev Neurol; 2017 May; 64(10):445-453. PubMed ID: 28497440 [TBL] [Abstract][Full Text] [Related]
7. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany. Ziemssen T; Lang M; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Lang S; Winkelmann VE; Ettle B; Schulze-Topphoff U; J Neurol; 2022 Jun; 269(6):3276-3285. PubMed ID: 34982201 [TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study. Tichá V; Kodým R; Počíková Z; Kadlecová P Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735 [TBL] [Abstract][Full Text] [Related]
10. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study. Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C; Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950 [TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis. Walczak A; Kurkowska-Jastrzebska I; Zakrzewska-Pniewska B; Dorobek M; Brola W; Zajdel R; Bartosik-Psujek H; Stasiolek M; Kulakowska A; Rusek S; Tutaj A; Glabinski A; Wlodek A; Kochanowski J; Ciach A; Siger M; Kurowska K; Wicha W; Nojszewska M; Podlecka-Pietowska A; Czajka A; Kapica-Topczewska K; Bielecki B; Maciagowska-Terela M; Stepien A Clin Neurol Neurosurg; 2019 Sep; 184():105453. PubMed ID: 31376776 [TBL] [Abstract][Full Text] [Related]
14. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait. Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422 [TBL] [Abstract][Full Text] [Related]
15. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA; Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis. Fakih AU; Sahraian MA; Paybast S; Naser Moghadasi A Mult Scler Relat Disord; 2023 Mar; 71():104564. PubMed ID: 36863084 [TBL] [Abstract][Full Text] [Related]
17. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ; PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. Pinheiro B; Guerreiro R; Costa J; Miguel LS J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777 [No Abstract] [Full Text] [Related]
19. Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran. Ouspid E; Razazian N; Moghadasi AN; Moradian N; Afshari D; Bostani A; Sariaslani P; Ansarian A Neurosciences (Riyadh); 2018 Apr; 23(2):129-134. PubMed ID: 29664454 [TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary. Biernacki T; Sandi D; Füvesi J; Fricska-Nagy Z; Kincses TZ; Ács P; Rózsa C; Dobos E; Cseh B; Horváth L; Nagy Z; Csányi A; Kovács K; Csépány T; Vécsei L; Bencsik K; PLoS One; 2022; 17(4):e0267346. PubMed ID: 35452476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]